Business Context and Reporting Period
This Form 8-K, filed by Scilex Holding Company on April 16, 2025, reports the entry into a material definitive agreement. The filing concerns an amendment to the previously announced Merger Agreement between Scilex's wholly-owned subsidiary, Semnur Pharmaceuticals, Inc., and Denali Capital Acquisition Corp. (Denali).
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are provided in this document.
Material Changes
On April 16, 2025, Semnur entered into Amendment No. 1 to the Merger Agreement with Denali. The amendment introduces the following material changes:
- Delisting and OTC Quotation: Modifies covenants to address the de-listing of Denali's securities (Parent Units, Class A Shares, and Warrants) from the Nasdaq Capital Market and their subsequent quotation on the OTC Markets Group, Inc.
- Extension of Combination Deadline: Requires Denali to amend its organizational documents to extend the period for completing a business combination to December 11, 2025, or a mutually agreed date.
- Extension of Outside Date: Extends the "Outside Date" (the final deadline to consummate the merger) to September 30, 2025, subject to potential further extension if an Extension Amendment is in effect.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing indicates that Denali will mail a definitive proxy statement/final prospectus to shareholders for approval of the Business Combination. The transaction remains contingent on shareholder approval and the successful consummation of the merger.
Risks and Contingencies: The filing includes extensive forward-looking statements and disclaimers. Key risks identified include:
- Failure to obtain shareholder approval from Semnur or Denali.
- Inability to consummate the Business Combination or termination of the Merger Agreement.
- Disruption of current plans and operations.
- Redemption requests by Denali shareholders affecting available capital.
- Inability to maintain listing on Nasdaq or OTC Markets post-transaction.
- General economic, political, and business conditions.
Investor Verification Checklist
- Verify the status of Denali's securities de-listing from Nasdaq and quotation on OTC Markets.
- Review the definitive proxy statement/final prospectus filed by Denali for detailed terms of the Business Combination.
- Confirm the record date for Denali shareholders to vote on the merger.
- Monitor for any unsolicited offers or legal proceedings that could interfere with the transaction.
- Assess the impact of the extended Outside Date (September 30, 2025) on the timeline for deal closure.